ClinicalTrials.gg
CompletedNCT00964535KINECOUpdated Feb 15, 2010

Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics

A Phase 1/2 interventional study of budesonide and formoterol 200/6 microg and budesonide and formoterol 200/6 microg in Asthma, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2010-02-15.

Sponsored by Orion Corporation, Orion Pharma · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.

Enrollment
7th of 19
87 · median 72
Started
2009
with 1 other
Phase 1/2
Only one
of the 21
Registered
1st of 21
by date

Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2009, is the only one in phase 1/2, and was the 1st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Asthma by Orion Corporation, Orion Pharma as a file.
02

Study summary

The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbohaler in terms of the drug absorbed into the bloodstream.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 18-60 years with documented diagnosis of asthma
  • Prebronchodilator (FEV1) at least 80% of the predicted value
  • The asthma should be stable on the same regular treatment for at least 4 weeks before screening.

Exclusion criteria

Exclusion Criteria:

  • Use of oral, parenteral or rectal within 4 weeks preceding the screening
  • Respiratory infection within 4 weeks preceding the screening
  • Any condition requiring regular concomitant treatment or likely to need concomitant treatment during the study with medicinal products which have pharmacokinetic interactions with budesonide
  • Any disorder or abnormal laboratory value or physical finding that may interfere with the interpretation of test results or cause a health risk for the subject if he/she participates in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Budesonide/formoterol Easyhaler

    Drug: budesonide and formoterol 200/6 microg

  • Experimental
    Charcoal and Budesonide/formoterol EH

    Drug: budesonide and formoterol 200/6 microg

  • Active comparator
    Symbicort Turbohaler

    Drug: budesonide and formoterol 200/6 microg

  • Active comparator
    Charcoal and Symbicort Turbohaler

    Drug: budesonide and formoterol 200/6 microg

Interventions

  • Drugbudesonide and formoterol 200/6 microg

    2 inhalations as a single dose

    Also known as: Budesonide/formoterol Easyhaler 200/6 microg/inhalation

  • Drugbudesonide and formoterol 200/6 microg

    2 inhalations as a single dose

    Also known as: Symbicort Turbohaler 200/6 microg/inhalation

  • Drugbudesonide and formoterol 200/6 microg

    2 inhalations as a single dose with the concurrent charcoal blockage

    Also known as: Budesonide/formoterol Easyhaler 200/6 microg/inhalation

  • Drugbudesonide and formoterol 200/6 microg

    2 inhalations as a single dose with the concurrent charcoal blockage

    Also known as: Symbicort Turbohaler 200/6 microg/inhalation

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters Cmax and AUCt of plasma budesonide and formoterol concentrations

    Time frame: within 24 h

07

Study locations

1 site
  • Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2009
First posted
Aug 25, 2009
Start
Sep 2009
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Last update
Feb 15, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00964535
First posted
Aug 25, 2009
Start date
Sep 2009
Primary completion
Feb 2010
Completion
Feb 2010
Last update
Feb 15, 2010

Study contacts

Ulla Sairanen, MSc
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion